Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Reference48 articles.
1. The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results;Lewis;Nat. Commun.,2024
2. Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis;Gammelgaard;Mol. Cancer,2024
3. Functionalized liposomes for targeted breast cancer drug delivery;Nel;Bioact. Mater.,2023
4. Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy;To;Drug Resist. Updates,2024
5. Cancer drug resistance: an evolving paradigm;Holohan;Nat. Rev. Cancer,2013
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Identification of chemical composition in Gnetum montanum extract and plasma components after oral administration in cynomolgus monkey by UPLC-Q-TOF-MS and its anti-tumor active components analysis;Journal of Pharmaceutical and Biomedical Analysis;2024-10
2. Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition;Molecules;2024-08-23
3. Study on Cytochrome P450 Metabolic Profile of Paclitaxel on Rats using QTOF-MS;Current Drug Metabolism;2024-07-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3